title: [Psychiatric disorders associated with use of imiquimod].
authors: Dermatologie, CHU de Nancy, bâtiment des spécialités médicales, allée du Morvan, 54500 Vandœuvre-Lès-Nancy, France. Electronic address: jl.schmutz@chu-nancy.fr.
authors: J-L
authors: JL
authors: Schmutz
authors: Centre de pharmacovigilance, CHU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France.
authors: P
authors: P
authors: Trechot
mesh_terms: D000369:Aged, 80 and over; D000634:Aminoquinolines / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy; D003704:Dementia / Q000139:chemically induced; D003863:Depression / Q000139:chemically induced; D005260:Female; D006801:Humans; D000077271:Imiquimod; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced*; D008875:Middle Aged; D011595:Psychomotor Agitation / Q000209:etiology; D012878:Skin Neoplasms / Q000188:drug therapy; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced
chemical_list: D000634:Aminoquinolines; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000077271:Imiquimod